A role of Foradil (formoterol fumarate) in therapy of bronchial asthma and chronic obstructive lung disease

1. Бронхиальная астма. Глобальная стратегия: совместный доклад Национального института сердце, легкие, кровь и Всемирной организации здравоохранения. Русская версия под общей редакцией академика А.Г.Чучалина. Пульмонология 1996; Прил. 1: 1-165.

2. Калманова Е.Н., Айсанов З.Р. Форадил и его место в терапии бронхиальной астмы. Там ж е 2001; 1:65-72.

3. Хронические обструктивные болезни легких. Федеральная программа. Рус. мед. журн. 2001; 9 [1 (120)]: 9-33.

4. Цой А.И., Архипов В.В. Вопросы клинической фармакологии Р2-адреностимуляторов. Там же [21 (140)]: 930-933.

5. Цой А.Н., Архипов В.В. Фармакодинамика стимуляторов р2-адренергических рецепторов. Пульмонология 2001; 4: 112-118.

6. Чучалин А.Г. Бронхиальная астма. М .; 1997; Т. 1-2.

7. Чучалин А.Г. Хроническая обструктивная болезнь легких. М .; 1998.

8. Anderson G.P. Formoterol: Pharmacology, molecular basis of agonism, and mechanism of long duration of highly Potent and selective agonist bronchodilatator. Life Sci. 1993; 52 (26): 2145-2160.

9. Barnes P.J. Bronchodilatators: basic Pharm acology. Chronic obstructive Pulmonary disease. London; 1995. 391-417.

10. Barnes P.J. Clinical outcome of adding long-acting beta-agonists to inhaled corticosteroids. ResPir. M ed. 2001; 95 (suPPl. B): S12-S16.

11. Barnes P.J. Effects of β2-agonists and steroids on β2-adrenorecePtor. Eur. ResPir. Rev. 1998; 8: 210-215.

12. β2-agonists. From Pharmacological ProPerties to everyday clinical Practice: International workshoP rePort. London; 2000.

13. Burgess C.D. et al. The extraPulm onary effects of increasing doses of formoterol in Patients w ith asthm a. Eu r. J. Clin. Pharmacol. 1998; 54 (2): 141-147.

14. Dahl R. et al. ComParison of the efficacy and safety of inhaled formoterol and iPratroPium bromide in Patients with C O PD . Am. J. ResPir. Crit. Care M ed. 2000; 161 (suPPl.): S489.

15. Hacki M.A. et al. Clinical exPerience over five years of daily theraPy with formoterol in Patients with bronchial asthma. Clin. Drug Invest. 1997; 14: 165-174.

16. KiPs J.C., O'Connor B.J., Inman M.D. et al. A long-termed study of the antiinflam m atory effect of low-dosed budesonide Plus formoterol versus high-dosed budesonide in asthma. Am . J. ResPir. Crit. Care M ed. 2000; 161: 996-1001.

17. Miller-Larsson A., Jansson P., Runstrom A., Brattsand R. Prolonged airw ay activity and imProved selectivity of budesonide Possibly due to esterification. Ibid. 162; 1455-1461.

18. Molimard M. et al. Long- and short-adrenorecePtor agonists: interactions in human contracted bronchi. Eur. ResPir. J. 1998; 11:583-588.

19. O'Connor B.J., Alkinan S.L., Barnes P.J. Tolerance to the nonbronchodilatator effects of inhaled β2-agonists in asthma. N. Engl. J. M ed. 1992; 327: 1204-1208.

20. Palmquist M. et al. ComParison of the relative efficacy of formoterol and salmeterol in asthmatic Patients. Am . J. ResPir. Crit. Care M ed. 1999; 160: 244-249.

21. Palmquist M. et al. Inhaled dry Powder formoterol and salmererol in asthm atic Patients: onset of action, duration of effect and Potency. Eur. ResPir. J. 1997; 10: 2484-2489.

22. Pauwels R.A. et al. Effect of inhaled formoterol and budesonide on exacerbations of asthm a. Form oterol and Corticosteroids Establishing TheraPy (F A C E T ) International Stud y GrouP. N. Engl. J. M ed. 1997; 337: 1405-1411.

23. Politiek M.J., Boorsma М., Aalbers R. ComParison of formoterol, salbutamol and salm eterol in methacholine-induced severe bronchoconstriction. Eur. ResPir. J. 1999; 13: 988-992.

24. Standards for the diagnosis and care of Patients with chronic obstructive Pulmonary disease A T S statement. Am . J. ResPir. Crit. Care M ed. 1995; 152 (5): 78-121.

25. The British guidelines on asthma management. Thorax 1997; 52 (suPPl.1): 1-21.